Impact of Obesity on Ovulatory Functions in Polycystic Ovarian Syndrome
|
|
- Avice Hunt
- 5 years ago
- Views:
Transcription
1 Med. J. Cairo Univ., Vol. 81, No. 1, December: , Impact of Obesity on Ovulatory Functions in Polycystic Ovarian Syndrome AHMED AL-SAWAF, M.D. and EMAN A. HUSSEIN, M.D. The Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University Abstract Background: Indeed the impact of obesity on female infertility is a topic of increasing importance in modern gynecological practice and extensive research is needed to reach well defined guidelines. In this current work the effect of obesity on ovulatory functions in pco was evaluated in 80 PCO patients attending the infertility outpatient clinic of Kasr Al-Aini Hospital. Patients and Methods: 80 PCO patients were selected according a restricted inclusion and exclusion criteria from Kasr Al-Aini infertility clinic in the period from July 2011 to March 2012, then divided into three groups according to BMI; Group (A) 38 patients with BMI <30Kg/m 2, Group (B) 24 patients with BMI 30-35kg/m 2, Group (C) 18 patients with BMI 35-40kg/m 2. Ovulatory function in the three groups was evaluated by folliculometry and day 21 progesterone. Basal hormonal profile on day 2 of the cycle (FSH, LH, E2, PRL and TSH) was also evaluated and statistically analyzed. Results: The results showed significant difference in the level of basal LH and prolactin (p-value <0.05) between the three groups; there was an inverse correlation between obesity and basal LH. PRL level was also significantly higher in the non obese groups. There was no significant difference in the level of basal FSH, E2 nor TSH. As regards to ovulatory functions; non obese group showed better ovulatory performance especially when monitored by day 21 progesterone (18.4% compared to 5.5% in the morbidly obese group). Conclusion: Obesity in PCO seems to increases the risk for anovulation most probably through the disruption of HPO axis by hyperandrogenism, and/or insulin resistance. Leptin may play a role through its direct effect on folliculogenesis. Weight reduction in PCO may improve ovulatory performance. Monitoring ovulation by folliculometry alone may not reflect accurate ovarian response and addition of day 21 progesterone should be considered to improve evaluation. Further studies and RCTs are needed to justify this conclusion. Key Words: Obesity PCO Hormonal profile Follicular maturation. Correspondence to: Dr. Ahmed Hussein Al Sawaf, hsawaf40@yahoo.com Introduction OBESITY is thought to result from a combination of environmental and genetic factors [1]. There are several methods for estimating body fat in adults; these include total body weight, waist circumference and hip circumference. Several indices of obesity have been derived from these measurements, including body mass index (BMI). BMI is the most widely used index of body fat in relation to body weight and height [2]. According to the WHO classification of obesity, increased BMI over 35, could be associated with serious health risks [1]. Obesity affects fertility through the presence of functional hyperandrogenism, hyperinsulinaemia and insulin resistant state, leading to increased free androgen availability, alterations of granulosa cell functions and follicular development [3]. Many studies have shown that many women with polycystic ovarian syndrome PCOS (between 38% and 88%) are overweight or obese [4]. Obesity is suggested to play a specific pathophysiological role in the development of PCOS [5]. The clinical features of PCOS are heterogenous and may change throughout the lifespan, starting from adolescence to post-menopausal age [3]. Many definitions were used to describe PCO syndrome, however, the most commonly used in clinical practice is the ROTERDAM CRITERIA which was used in the current study. In 2003 in Rotterdam, Netherlands, a consensus meeting between the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM) The Rotterdam ESHRE/ASRM Consensus Workshop defined PCOS; Affected individuals must have two out of the following three criteria: 1- Oligo- and/or ano- 983
2 984 Impact of Obesity on Ovulatory Functions in Polycystic Ovarian Syndrome vulation, 2- Hyperandrogenism (clinical and/or biochemical), and 3- Polycystic ovaries on sonographic examination with one ovary being sufficient for diagnosis [6]. Several studies have demonstrated higher rates of in-vitro fertilization IVF cycle cancellation prior to oocyte retrieval in overweight and obese women especially obese PCO [7-9]. A higher cancellation rate of 25.3% was found in the morbidly obese group compared to 10.8% in the normal weight and overweight women [10]. The precise mechanisms for increased gonadotrophins requirements and higher cancellation rate in obese women undergoing IVF remain unclear. However it has been suggested that abnormal LH and FSH levels may result in impaired ovarian response and decreased folicular maturation in this population [9]. Indeed the impact of obesity on female infertility is a topic of increasing importance in modern gynecological practice and extensive research is needed to reach well defined guidelines. In this current work the effect of obesity on ovulatory functions in pco was evaluated in 3 groups of women attending the infertility outpatient clinic of Kasr Al-Aini Hospital: (Group A: BMI <30kg/ m 2, Group B: BMI between kg/m 2, Group C: BMI between 35-40kg/m). Patients and Methods Place: Kasr AL-Aini infertility Outpatient Clinic, Cairo University, Egypt. Design: This is a prospective comparative study carried out on 80 PCO patients who underwent foliculometry and hormonal profile to assess their ovulation in the period from July 2011 to March 2012 at Kasr Al-Aini Infertility Outpatient Clinic. Inclusion criteria: Age group: years old. Parity: Variable. PCO patient according to Roterdam criteria. Agreement for participation in the study. Exclusion criteria: Age: <20 years and >35 years old. Any history of diseases that may affect ovulatory functions as thyroid, hepatic or renal problems problems. Patients who had previous operations on the ovary as cases with ovarian drilling. Written consents were taken from all cases according to the code of clinical research ethics of Kasr Al-Aini Hospitals. Methods: All participants were subjected to the following: - Full history taking with special emphasis on; age, parity, recent medications with specialy drugs that may affect ovulatory functions and special habits of medical importance e.g. smoking. - Full clinical examination including weight, height and BMI which was calculated as weight (in kilograms) divided by the height in meters squared [1]. Patients were divided into 3 groups according to BMI: Group A: 38 cases with BMI<30kg/m 2. Group B: 24 cases with BMI between 30 and 35kg/m 2. Group C: 18 cases with BMI between: 35 and 40kg/m 2. All participants were given induction of ovulation by clmiphene citrate 50mg twice daily for 5 days on day 2 or 3. Metformin 500mg tds was also given for one month. Ovulation was monitored in the 3 groups by serial songraphy (Toshiba Famio 5 6MHz) starting from day 9 or 10 and serum progesterone day 21. Ovulation was positive when the follicle size reached 16mm or more (16-21 mm) or day 21 progesterone exceeded 12ng/ml. Basal hormones (FSH, LH, E2, PRL and TSH) were also evaluated in the 3 groups and statistically analysed using computer programs Microsoft Excel version 7 (Microsoft corporation, NY, USA) and SPSS (Statistical package for the social science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows. Statistical analysis of the data: The results were analyzed by ANOVA. Results The demographic data of the cases included in the study is presented in Table (1). It is evident that there is no significant difference between the three groups regarding their age or parity.
3 Ahmed Al-Saw af & Eman A. Hussein 985 Table (1): Age (years) and parity of the the three groups of patients classified according to BMI. BMI >30 38 patients BMI= patients BMI= patients p-value * Significance Age: Mean SD NS SE Parity: Mean SD I70 NS SE The basal hormonal profile on day 2 of the cycle is shown in Table (2). The results showed significant difference in the level of basal LH and prolactin (p-value <0.05). No significant difference was observed regarding basal FSH, E2 nor TSH (p-value >0.05). Table (2): Basal hormonal profile on day 2 of the cycle of FSH, LH, E2, PRL and TSH in the three groups of patient with different BMI. BMI >30 38 patients BMI= patients BMI= patients p-value* Significance FSH: Mean SD NS SE LH: Mean SD S SE E2: Mean SD NS SE PRL: Mean SD S SE TSH: Mean SD NS SE Upon studying ovulation in the three groups of patients with different BMI (Table 3), it was found that ovulation was better in the non obese group, however, this result did not show a statistical significance (p-value >0.05). Upon studying ovulation by day 21 progesterone (Table 4), it was obvious that ovulation was better in the non obese groups and this result was statistically significant. Table (3): U/S evidence of ovulation in the three groups according to follicular size. No Ovulation Yes Total p-value Groups: (23.6%) (20.8%) 24 > (22.2%) 18 Total ( 22.5%) 80
4 986 Impact of Obesity on Ovulatory Functions in Polycystic Ovarian Syndrome Table (4): U/S evidence of ovulation according to day 21 progesterone No Ovulation Yes Total p-value Groups: (18.42%) (16.66%) 24 > (5.55%) 18 Total (15%) 80 Discussion Most of the studies about obesity and infertility have been controversial and this may be attributed to a vast array of factors such as type of the study, sample size, variation in methodology and statistical analysis [11]. The present study was carried on 80 patients attending the infertility outpatient clinic of Kasr Al-Aini Hospitals. They were divided according to their BMI into three groups: First with BMI <30, second with BMI=30-35 and third group with BMI= Regarding the patient demographic data, there was no significant difference among the three groups included for their age and parity i.e. patients were matched as regards to age and parity. Regarding the basal hormonal profile, there was no significant difference in the levels of day 2 FSH, E2 nor TSH between the three groups, but there was a statistically significant increase regarding day 2 LH and PRL in the non obese group having BMI>30. This inverse correlation between BMI and basal LH was observed in similar studies; this result agrees with Pagán et al., [12] who studied twentyfour women with PCOS across a spectrum of BMIs with frequent blood sampling, IV administration of GnRH (75ng/kg), and SC administration of the NAL-GLU GnRH antagonist (5 gg/kg) in the General Clinical Research Center at an Academic Hospital coming out with results that illustrates the inverse correlation between BMI and mean LH, LH/FSH, and LH pulse amplitude. They also suggested that the effect of BMI on LH is mediated at a pituitary and not a hypothalamic level in PCOS as they noticed that the pituitary response to a weight-based dose of GnRH is inversely related to BMI in PCOS. This conclusion was also obtained by Bohlke et al., [13] who assessed the relationship between body mass index (BMI) and basal LH and the LH- FSH ratio revealing the same inverse association between BMI and basal LH levels but the study was on normally menstruating women and not on PCO patients. However, on the other hand Micah et al., [14] and Sathya et al., [15], who studied the impact of BMI on the outcome of ICSI cycles (they classified their patients only according to their BMI without focusing on pco patients), have stated in their results that the level of basal LH did not differ between obese and lean women. Our results also revealed significantly lower levels of prolactin in the obese group compared to the non-obese candidates. This finding is also an important secondary outcome observed in this study. As for basal FSH, E2 and TSH; results showed no significant difference between the three groups with different BMI. This result agrees with the findings observed by Sathya et al., [15]. In their study which focused on impact of obesity on IVF outcome, they recorded non significant difference in basal hormones with different BMI. On the contrary our findings may disagree with other studies as Loveland et al., who performed retrospective analysis on one hundred thirty-nine women <40 years old undergoing IVF cycles with fresh embryo transfers. They found that there is a decrease in basal FSH levels in the obese patients compared to non obese partners [16]. Also Giovanni et al., found lower basal FSH and estradiol levels in obese patients in their study that was carried on 22 patients with BMI >30 to document the hormonal differences in obese women [17]. In the second part of our work ovulation in the three groups was monitored by direct demonstration of a growing follicle using the trans-vaginal U/S. Although ovulation seemed to be better in non obese group (23.6%), yet, this result was not statistically significant. When ovulation was monitored by day 21 progesterone; ovulation was much better in the non obese group (18.3%), compared to the other groups. Ovulation was worst in the morbidly obese group (5.5%). Our results may agree with a prospective cohort study carried by Walter et al., These authors found that; in anovulatory women with PCOS resumption of ovulation was associated with early and consistent loss of intra-abdominal fat (12.4 versus 5.0% at 3 months and 18.5 versus 8.6% at 6 month) [18].
5 Ahmed Al-Saw af & Eman A. Hussein 987 There are also several studies that agree with our results such as those carried by Norman et al., who concluded that there is a definite relationship between anovulation and body BMI [19]. Our results may be attributed to abnormal leptin levels in obese patients which is believed to play a role in ovarian folliculogenesis. Human leptin is a protein of 167 amino acids. It is manufactured primarily in the adipocytes of white adipose tissue, and the level of circulating leptin is directly proportional to the total amount of fat in the body [20]. Leptin participates in regulation of ovarian folliculogenesis indirectly via control of LH and FSH secretion. More recent evidence suggests that leptin also has direct regulatory actions on the developing follicle. The presence of leptin receptors on follicular cells, including oocytes, and early pre-implantation embryos suggests that leptin may play a direct physiologic role in follicular maturation, oocyte development [21]. Because circulating leptin levels are directly related to body adiposity, elevated leptin concentrations associated with obesity may partly explain the negative impact of obesity on ovulation through its effect on FSH secretion and its direct effect on the follicles. There are several biological mechanisms through which obesity may increase the risk for anovulation. These mechanisms center on the HPO axis, which regulates both the menstrual cycle and ovulatory function through a complex hormonal regulation system. The two main disturbances to the HPO axis occur through either hyperandrogenism or insulin resistance [22]. Hyperandrogenism is a biological condition where there is an excess production or secretion of androgens, which include sex hormones [3]. Adipose tissue has been shown to have the potential to alter the secretion of sex hormones, given its essential role in both androgen production and in the conversion of androgens into other sex hormones [22]. In the same direction, insulin resistance and hyperinsulinemia can lead to disturbance in ovulatory function. The ovary is a target organ for insulin to stimulate the production of sex hormones [22]. This increased insulin level will negatively affect follicular maturation through increasing free insulin-like growth factor 1. In conclusion: There is a biological evidence supporting the hypothesis that obesity increases the risk for anovulation in PCOS through the disruption of HPO axis by hyperandrogenism, and/or insulin resistance [22] or through obnormal levels of leptin [21]. Therefore weight reduction in PCOS may improve ovulatory functions and should be advised complementary to induction protocols. However, further research studies are still required to elucidate the role of individual members of the complex endocrine system that controls these relationships. References 1- World Health Organization: Obesity: Preventing and managing the global epidemic, WHO technical report series 894. Geneva, Switzerland: World Health Organization, DOUGLAS T., NORRIS L.E. and OSTER R.A.: Difference in dietary intake between women with polycystic ovary syndrome and healthy controls Fertil. Steril., 86 (2): 411-7, PASQUALI R., PELUSI C., GENGHINI S., CACCIARI M. and GAMBINERI A.: Obesity and reproductive disorders in women. Hum. Reprod Update Online, 9: , LEGRO R.S.: The genetics of obesity, lessons for polycystic ovary syndrome. Annals of New York Acadmy of Sciences Online, 900: , GAMBINERI A., PELUS C., VICENNATI V., PAGOTTO U. and PASQUALI R.: Obesity and the polycystic ovary syndrome. Int. J. Obesity. Rel. Metab. Disord., 26: , FAUSER B.C., TARLATZIS B.C., REBAR R.W., LEGRO R.S., BALEN A.H., LOBO R., CARMINA E., CHANG J., YILDIZ B.O., LAVEN J.S., BOIVIN J., PETRAGLIA F., WIJEYERATNE C.N., NORMAN R.J., DUNAIF A., FRANKS S., WILD R.A., DUMESIC D. and BARN- HART K.: Consensus on women's health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ES- HRE/ASRM-Sponsored 3 rd PCOS Consensus Workshop Group. Fertil. Steril. Jan., 97 (1): e25, WANG J.X., DAVIES M. and NORMAN R.J.: Body mass and probability of pregnancy during assisted reproduction treatment: Retrospective Study BMJ Online, 321: , FEDORCSAK P., DALE P.O., STORENG R., ERTZEID G., BJERCKE S., OLDEREID N., OMLAND A.K., ABY- HOLM T. and TANBO T.: Impact of overwight and under weight on assisted reproduction treatment. Hum. Reprod. Online, 19: , SPANDORFER S.D., KUMP L. and GOLDSCHLAG D.: Obesity and in vitro fertilization: Negative influences on outcome. J. Reprod. Med. Online, 49: , DOKRAS A., BAREDZIAK L., BLAINE J., SYROP C., VAN VOOKHIS B.J. and SPARKS A.: Obestetric outcomes after in-vitro fertilization in obese and morbidly obese women. Obstet. Gynecol. Online, 180: 61-69, ADAM H. BALEN and ST JAMES: Assisted conception, in Adam H. Balen (Eds): Infertility in practice, third edition, in Forma Healthcare, PAGÁN Y.L., SROUJI S.S., JIMENEZ Y., EMERSON A., GILL S. and HALL J.E.: Inverse relationship between
6 988 Impact of Obesity on Ovulatory Functions in Polycystic Ovarian Syndrome luteinizing hormone and body mass index in polycystic ovarian syndrome: Investigation of hypothalamic and pituitary contributions. J. Clin. Endocrinol. Metab. Apr., 91 (4): Epub. Jan., 24, BOHLKE K., CRAMER D. and BARBIERI R.L.: Relation of luteinizing hormone levels to body mass index in premenopausal women. Fertil. Steril., 69: 500, MICAH J. HILL, STEVE HONG and JOHN L. FRAT- TARELLI: Body Mass Index Impacts in Vitro Fertilization Stimulation, ISRN Obstetrics and Gynecology, Volume, Article ID , 5 pages, SATHYA A., BALASUBRAMANYAM S., GUPTA S. and VERMA T.: Effect of body mass index on in vitro fertilization outcomes in women. J. Hum. Reprod. Sci. Sep., 3 (3): 135-8, LOVELAND J.B., MCCLAMROCK H.D., MALINOW A.M. and SHARARA F.I.: Increased body mass index has a deleterious effect on in vitro fertilization outcome. Journal of Assisted Reproduction and Genetics, 18: , GIOVANNI LAW D.C., MACLEHOSE R.F. and LONG- NECKER M.P.: Obesity and timeto pregnancy. Hum. Reprod., 22 (2): , WALTER K.H. KUCHENBECKER, HENK GROEN, SOPHIE J. VAN ASSELT, JOHANNA H.T. BOLSTER, J. ZWERVER, RIEMER H.J. SLART, ERIK J. VD JAGT, ANNEKE C. MULLER KOBOLD, BRUCE H.R. WOLFFENBUTTEL, JOLANDE A. LAND and ANNE- MIEKE HOEK: In Women With Polycystic Ovary Syndrome and Obesity, Loss of Intra-abdominal Fat is Associated with Resumption of Ovulation; Human Reproduction, 26 (9): , NORMAN R.J., NOAKES M., WU R., DAVIES M.J., MORAN L. and WANG J.M.: Improving reproductive performance in overweight/obese women with effective weight management. Hum. Reprod. Update Online, 10: , ZHANG F., BASINSKI M.B. and BEALS J.M.: Crystal structure of the obese protein leptin-e100. Nature May, 387 (6629): 206-9, BRANNIAN J.D. and HANSEN K.A.: Leptin and ovarian folliculogenesis: Implications for ovulation induction and ART outcomes. Semin. Reprod. Med., 20 (2): , BREWER C.J. and BALEN A.H.: The adverse effects of obesity on conception and implantation. Reproduction, 140 (3): , 2010
METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationPrevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study
Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Mousa Mohsen Ali* Wasan Ghazi* HayderAamerAbboud^ *Kerbala University, College of Medicine, Gynecology
More information3. Metformin therapy for PCOS
1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationObesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation
IN VITRO FERTILIZATION Obesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation Allison Styne-Gross, M.D., a Karen Elkind-Hirsch, Ph.D., b
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationNature and Science 2017;15(8)
Prognostic Value of Day 3 Luteinising Hormone (LH) in the prediction of Ovarian Response in Patients with Polycystic Ovary syndrome Mohammed Samir Fouad 1 ; Mohammed Said El-Shorbagy 2, Mohammed Mohammed
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationThe prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria
Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationThe Effect of Vitamin D Replacement Therapy on Serum Leptin and Follicular Growth Pattern in Women with Clomiphene Citrate Resistant Polycystic Ovary
Med. J. Cairo Univ., Vol. 84, No. 2, June: 85-89, 2016 www.medicaljournalofcairouniversity.net The Effect of Vitamin D Replacement Therapy on Serum Leptin and Follicular Growth Pattern in Women with Clomiphene
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationS. AMH in PCOS Research Insights beyond a Diagnostic Marker
S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More informationRotterdam Criteria 9/30/2017. A Changing Paradigm in PCOS. Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause?
Disclosure Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause? Fractyl laboratories, Inc Anuja Dokras, MD., Ph.D. Professor of Obstetrics and Gynecology Director PENN PCOS
More informationPregnancy outcome in women with polycystic ovary syndrome
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Nivedhitha VS et al. Int J Reprod Contracept Obstet Gynecol. 2015 Aug;4(4):1169-1175 www.ijrcog.org pissn 2320-1770 eissn
More informationDetermining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)
Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.
More informationInfertility: A Generalist s Perspective
Infertility: A Generalist s Perspective Learning Objectives Fertility and Lifestyle: Patient education Describe the basic infertility workup Basic treatment strategies unexplained Heather Huddleston, MD
More informationReproductive outcome in women with body weight disturbances
Reproductive outcome in women with body weight disturbances Zeev Shoham M.D. Dep. Of OB/GYN Kaplan Hospital, Rehovot, Israel Weight Status BMI (kg/m 2 ) Underweight
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationManipal & Apollo Spectra Hospital. Special Interest:Laparoscopy & Bariatric Surgery
Name: Dr M G Bhat Designation: Consultant Surgeon Affiliation: Manipal & Apollo Spectra Hospital Special Interest:Laparoscopy & Bariatric Surgery When should we suggest Bariatric Surgery in PCOD? 17 June
More informationPrevalence of polycystic ovarian syndrome in the Buraimi region of Oman
Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine
More informationUterus & Ovary 2015; 2: e904. doi: /uo.904; 2015 by Ahmed M Maged, et al.
RESEARCH ARTICLE Phytoestrogens as an alternative to estradiol in reversing the antiestrogenic effect of clomid on endometrium in ovulation induction in cases of polycystic ovarian syndrome (PCOS) Ahmed
More informationGynecology & Reproductive Health
Research Article Gynecology & Reproductive Health ISSN 2639-9342 Combined Clomiphene Citrate-Metformin Versus Letrozole-Metformin in Achieving Pregnancy among Women with Polycystic Ovary Syndrome Shrivastava
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the Investigation and Management of Polycystic Ovary Syndrome Author: Contact Name and Job Title
More informationRelation of luteinizing hormone levels to body mass index in premenopausal women
FERTILITY AND STERILITY VOL. 69, NO. 3, MARCH 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Relation of luteinizing
More informationRelationship between Energy Expenditure Related Factors and Oxidative Stress in Follicular Fluid
Original Article Relationship between Energy Expenditure Related Factors and Oxidative Stress in Follicular Fluid Abstract This study evaluated the impact of body mass index (BMI), total calorie intake
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationSCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY
SCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY Sahar Mansour Ibrahim, Yossria Ahmed Elsayed, Reda Esmail Reyad 4 and Hanan Fahmy Azzam 1* 2 3 1 Assistant Lecturer,
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationInfertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery
Macut D, Pfeifer M, Yildiz BO, Diamanti-Kandarakis E (eds): Polycystic Ovary Syndrome. Novel Insights into Causes Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications
More informationComparative study of metabolic profile of women presenting with polycystic ovary syndrome in relation to body mass index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Akshaya S et al. Int J Reprod Contracept Obstet Gynecol. 2016 Aug;5(8):2561-2565 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationwww.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second
More informationPage 196. Corresponding Author: Swati Garg, Volume 3 Issue - 4, Page No
ISSN- O: 2458-868X, ISSN P: 2458 8687 Index Copernicus Value: 49. 23 SJIF Impact Factor: 4.271 International Journal of Medical Science and Innovative Research (IJMSIR) IJMSIR : A Medical Publication Hub
More informationImpact of Body Mass Index on Implantation Rate in ICSI Cycles
The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (10), age 7730-7736 Impact of Body Mass Index on Implantation Rate in ICSI Cycles Osama Alsaied Ali, Bassem Ragab Abdel-Aziz, Abdallah Mohammed
More informationApproach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD
Approach to ovulation induction and superovulation in women with a history of infertility Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationEstimation of serum 25 hydroxy vitamin D level and its correlation with metabolic and endocrine dysregulation in women with PCOS
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Solanki V et al. Int J Reprod Contracept Obstet Gynecol. 2017 Jul;6(7):3085-3090 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20172939
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome
More informationCREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University
CREATING A PCOS TREATMENT PLAN Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University PCOS: CREATING A TREATMENT PLAN Good treatment plans are based on sound and complete evaluations History of
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationMetformin in early pregnancy and abortions. Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland
Metformin in early pregnancy and abortions Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland PCOS and miscarriage risk Metformin and miscarriage risk
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationNew PCOS guidelines: What s relevant to general practice
New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris
More informationBody mass index and basal androstenedione are independent risk factors for miscarriage in polycystic ovary syndrome
Yang et al. Reproductive Biology and Endocrinology (2018) 16:119 https://doi.org/10.1186/s12958-018-0438-7 RESEARCH Open Access Body mass index and basal androstenedione are independent risk factors for
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationOriginal Article Pregnancy Complications - Consequence of Polycystic Ovary Syndrome or Body Mass Index?
Chettinad Health City Medical Journal Original Article Puvithra T*, Radha Pandiyan**, Pandiyan N*** *Assistant Professor, **Senior Consultant & Associate Professor, ***Prof & HOD, Department of Andrology
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationInfertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary
Subfertility Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Infertility affects about 15 % of couples. age of the female. Other factors that
More informationROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME
ORIGINAL ARTICLE ROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME 1 2 3 Samdana Wahab, Farnaz, Rukhsana Karim ABSTRACT Objective: To assess the role of Metformin in Polycystic ovarian syndrome (PCOS).
More informationPrevalence and symptomatology of polycystic ovarian syndrome in Indian women: is there a rising incidence?
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Choudhary A et al. Int J Reprod Contracept Obstet Gynecol. 2017 Nov;6(11):4971-4975 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20175010
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationThe Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page
The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page 1278-1288 Anti-Mullerian Hormone: An Indicator for the Severity of Polycystic Ovarian Syndrome Yehia Abd-Elsalam Wafa 1, Mohamed
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationObjectives 06/21/18 STILL A PLACE FOR PILLS DON T IVF EVERYTHING. Clomiphene citrate and Letrozole. Infertility Case Studies. Unexplained Infertility
STILL A PLACE FOR PILLS DON T IVF EVERYTHING Jeff Roberts M.D. Co-Director, Pacific Centre for Reproductive Medicine Objectives 1 2 3 4 5 Clomiphene citrate and Letrozole Infertility Case Studies Unexplained
More informationThe impact of obesity on reproduction in women with polycystic ovary syndrome
DOI: 10.1111/j.1471-0528.2006.00990.x www.blackwellpublishing.com/bjog Review article The impact of obesity on reproduction in women with polycystic ovary syndrome R Pasquali, A Gambineri, U Pagotto Division
More informationNew York Science Journal 2017;10(8)
Clomiphene Citrate Stair Step Protocol with Phytoestrogen Vs. Traditional Protocol in Patient with Polycystic Ovary Syndrome Asem A. Mousa (MD) 1, Mohamed A. Mohamed (MD) 1, Waleed A. Saad (MBBCH) 2 2
More informationEndocrine control of female reproductive function
Medicine School of Women s & Children s Health Discipline of Obstetrics & Gynaecology Endocrine control of female reproductive function Kirsty Walters, PhD Fertility Research Centre, School of Women s
More informationPolycystic ovary syndrome (PCOS) Polycystic ovary syndrome: Why are women at increased risk of type 2 diabetes? Article.
Article Polycystic ovary syndrome: Why are women at increased risk of type 2 diabetes? Julie Tomlinson Citation: Tomlinson J (2016) Polycystic ovary syndrome: Why are women at increased risk of type 2
More informationIMPACT OF NUTRITION ON GYNECOLOGICAL HEALTH OF FEMALE ADOLESCENTS
IMPACT OF NUTRITION ON GYNECOLOGICAL HEALTH OF FEMALE ADOLESCENTS Kedikova S. MD, PhD Medical University Sofia, Bulgaria University Hospital Maichin dom Sofia NUTRITION WHO - Nutrition is the intake of
More informationDiagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome
Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO
More informationClinical Profile Polycystic Ovarian Syndrome Cases
ORIGINAL RESEARCH www.ijcmr.com - 100 Cases Himabindu Sangabathula 1, Neelima Varaganti 1 ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is most common endocrine disorders of reproductive age
More informationTHE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE
NSave Nature to Survive 9(1): 01-06, 2014 www.thebioscan.in THE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE K. ROY GEORGE AND N.
More informationThe impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome
Human Reproduction Vol.16, No.6 pp. 1086 1091, 2001 The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome Péter Fedorcsák 1, Per Olav Dale,
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69 Effect of Metformin Only versus Effect of Metformin and Corticosteroids after Laparoscopic Ovarian Drilling on Ovulation
More informationArticle Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive technologies
RBMOnline - Vol 18. No 6. 2009 856-863 Reproductive BioMedicine Online; www.rbmonline.com/article/3950 on web 30 March 2009 Article Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive
More informationEpidemiological correlates among women with Polycystic ovary syndrome in South India
ISSN: 2347-3215 Volume 2 Number 9 (September-2014) pp. 181-186 www.ijcrar.com Epidemiological correlates among women with Polycystic ovary syndrome in South India Pratik Kumar Chatterjee 1, P.Prasanna
More informationEvidence that obesity alters the quality of oocytes and embryos
Pathophysiology 15 (2008) 115 121 Review Evidence that obesity alters the quality of oocytes and embryos Rebecca L. Robker Discipline of Obstetrics and Gynaecology, Research Centre for Reproductive Health,
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationWEIGHT GAIN DURING MENOPAUSE EMERGING RESEARCH
MENOPAUSE WHEN DOES IT OCCUR? The cessation of the menstrual cycle for one year. WEIGHT GAIN DURING MENOPAUSE EMERGING RESEARCH Jan Schroeder, Ph.D. Chair of The Department of Kinesiology California State
More informationJournal of American Science 2013;9(12)
Early Clomiphene Citrate for Induction of Ovulation in Women with Polycystic Ovary Syndrome a randomized controlled trial Elguindy A. 1, Hussein M. 1 * and El-Shamy R 2 1 Department of Obstetrics and Gynecology,
More informationAnti-Mullerian hormone (AMH) as predictor of ovarian reserve
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Shembekar CA et al. Int J Reprod Contracept Obstet Gynecol. 2017 Sep;6(9):4006-4010 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20174053
More informationMetformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome
IJMS Vol 36, No 2, June 2011 Original Article Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome Marzieh Farimani Sanoee 1, Nosrat Neghab 1, Soghra
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome What is Polycystic Ovarian Syndrome? Polycystic Ovarian Syndrome (PCOS) is characterized by the presence of multiple ovarian cysts and excess androgen production. Clinical Features
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationCorrelation Between Insulin, Leptin and Polycystic Ovary Syndrome
Original Article Correlation Between Insulin, Leptin and Polycystic Ovary Syndrome Mohamed Nabih El Gharib, Thoraya Elsayed Badawy 1 Departments of Obstetrics and Gynecology, 1 Clinical Pathology, Faculty
More informationInsulin sensitizers in PCOS syndrome
Insulin sensitizers in PCOS syndrome Chiara Riviello,MD Specialista in Ginecologia e Ostetricia Specialista in Medicina Legale Medico Agopuntore www.chiarariviello.it/ dottoressa@chiarariviello.it Milan,
More informationPolycystic Ovary Disease: A Common Endocrine Disorder in Women
Polycystic Ovary Disease: A Common Endocrine Disorder in Women Paul Kaplan, M.D. Clinical Professor of Reproductive Endocrinology - OHSU Courtesy Senior Research Associate, Human Physiology University
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationThe Relation between Diverse Phenotypes of PCOS with Clinical Manifestations, Anthropometric Indices and Metabolic Characteristics
ORIGINAL ARTICLE The Relation between Diverse Phenotypes of PCOS with Clinical Manifestations, Anthropometric Indices and Metabolic Characteristics Seyedeh Hajar Sharami 1, Zahra Abbasi Ranjbar 2, Forozan
More informationHigh-quality embryos retain their implantation capability in overweight women
Reproductive BioMedicine Online (2010) 21, 706 711 www.sciencedirect.com www.rbmonline.com ARTICLE High-quality embryos retain their implantation capability in overweight women Jacob Farhi 1, *, Avi Ben-Haroush
More informationThe serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing
More informationHonorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive FIGO s Distinguished Merit Award for Services towards women s health.
Prof.Duru Shah Founder President The PCOS Society (India) President Elect of the Indian Society for Assisted Reproduction (ISAR) Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationObstretics and Gynaecology. Nikita M. Singh A, Deepak Kamat B, Parth Patel A, Tupe N.B C
Original Article National Journal of Medical and Dental Research, Jan.-March. 2017: Volume-5, Issue-2, Page 112-117 DEMOGRAPHIC PROFILE, PREVALENCE AND TREATMENT MODALITIES RECEIVED BY PATIENTS WITH POLYCYSTIC
More informationPolycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology
Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about
More informationAssisted reproduction in polycystic ovarian disease: A multicentric trial in India
Original Article Assisted reproduction in polycystic ovarian disease: A multicentric trial in India Pratap Kumar, Natasha Nawani, Narendra Malhotra, Jaideep Malhotra, Madhuri Patil, K Jayakrishnan, Sujata
More informationNorth Carolina Center for Reproductive Medicine, Cary, North Carolina
FERTILITY AND STERILITY VOL. 75, NO. 3, MARCH 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Metformin treatment
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationJMSCR Vol 06 Issue 09 Page September 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i9.53 Role of Anti-Mullerian Hormone
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More information